Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-30

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall goal of this clinical trial is to evaluate the causality relationship between the non vagus nerve stimulation waveform parameters and the therapeutic effect. Thus, unlocking a pathway to optimize parameters that maximize the benefits of therapy and minimize unwanted side effects. The experimental design includes the analysis of physiological signals, clinical biomarkers of disease, and clinical outcomes to determine the most effective measures for the monitoring, optimization, and personalization of non vagus nerve stimulation in systemic lupus erythematosus disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vagus Nerve Stimulation for Systemic Lupus Erythematous

NCT05315739

Systemic Lupus Erythematosus Autonomic Dysfunction Autonomic Neuropathy +1 more

COMPLETED NA

Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis Systemic Sclerosis

NCT04971018

Systemic Sclerosis

COMPLETED NA

VNS for Long-COVID-19

NCT05630040

Post-COVID-19 Syndrome Postural Tachycardia Syndrome Dysautonomia

COMPLETED NA

Non-invasive Modulation of Autonomic Cardiac Nervous System

NCT04057508

Autonomic Nervous System Heart Rate Variability Muscle Sympathetic Nerve Activity

UNKNOWN NA

Efficacy of Non-invasive Vagus Nerve Stimulation for Axial Spondyloarthritis Resistant to Biotherapies

NCT04286373

Axial Spondyloarthritis

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Lupus Erythematosus Autoimmune Disorder Vagus Nerve Autonomic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

VaNeSA is a multicentre, national, randomized, double-blind, parallel-group, placebo-controlled, outpatient study.

Primary Study Purpose

SCREENING

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham

Control group to be subjected to sham stimulation.

Group Type SHAM_COMPARATOR

Sham Intervention

Intervention Type DEVICE

Sham stimulation

30 hertz (Hz) Stimulation

Group of patients treated via 30Hz transcutaneous electrical nerve stimulation

Group Type EXPERIMENTAL

Parasym 30Hz

Intervention Type DEVICE

Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz

1Hz Stimulation

Group of patients treated via 1Hz transcutaneous electrical nerve stimulation

Group Type EXPERIMENTAL

Parasym 1Hz

Intervention Type DEVICE

Transcutaneous auricular vagus nerve stimulation of 1Hz

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Parasym 1Hz

Transcutaneous auricular vagus nerve stimulation of 1Hz

Intervention Type DEVICE

Parasym 30Hz

Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz

Intervention Type DEVICE

Sham Intervention

Sham stimulation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Systemic lupus erythematosus (SLE) (defined by the American College of Rheumatology- or SLICC criteria)
* Musculoskeletal pain ≥ 4 on a non-anchored VAS 10 cm scale
* BILAG C on Musculoskeletal Domain of the BILAG 2004
* If on corticosteroids, the dose must be stable and ≤ 10mg/day (prednisone or equivalent) for at least 28 days before baseline,
* If on background immunosuppressive treatment the dose must be stable for at least 28 days before baseline
* Able and willing to give written informed consent and comply with the requirements of the study protocol.

Exclusion Criteria

* Treatment with rituximab within one year of baseline as it is related to lymphocyte depletion that could alter the result of the biomarker study (subjects with previous treatment with rituximab can enter study only with documentation of B cell repletion).
* Treatment with cyclophosphamide within 2 months of baseline as it is related to lymphocyte depletion that could alter the result of the biomarker study.
* Expectation to increase steroids and/or immunosuppressive treatment.
* Anti-phospholipid syndrome.
* Fibromyalgia (fibromyalgia will be defined as a score \> 13 on the Fibromyalgia Symptom Scale), chronic fatigue syndrome.
* Treatment with an anti-cholinergic or sympathicomimetic medication, including over the counter medications.
* Implantable electronic devices such as pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators.
* Joint replacement within 60 days prior to study enrolment or planned within the course of the study.
* Any planned surgical procedure requiring general anaesthesia within the course of the study.
* Intra-articular cortisone injections within 28 days of the start of study.
* Chronic inflammatory disorders apart from SLE affecting the joints.
* Investigational drug and/or treatment during the 28 days or seven half-lives of the investigational drug prior to the start of study drug dosing (Day 0), whichever is the greater length of time.
* Active infection including hepatitis B, hepatitis C or HIV at baseline due to high prevalence of neuropathy.
* Any condition which, in the opinion of the investigator, would jeopardize the subject's safety following exposure to a study intervention.
* Pregnancy or lactation.
* Haemoglobin below 9.0 gm/dL (by the most recent CBC) as anaemia is related to no- neurogenic orthostatic hypotension and increases cardiovascular symptoms in COMPASS 31 scale
* Comorbid disease that may require administration of corticosteroid use.
* Inability to comply with study and follow-up procedures.
* Known cardiac arrhythmia, severe cardiac disease or neurodegenerative disease.
* Known or confirmed at baseline screening peripheral or autonomic nervous system involvement, including LES-related, toxic polyneuropathies, metabolic neuropathies (including diabetes), etc.
* Previous experience with vagus nerve stimulation devices

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No